welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!
approved for marketing

Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy

key information

study id #: NCT02592941

condition: Duchenne Muscular Dystrophy

status: approved for marketing

purpose:

The expanded access program will provide access to treatment with deflazacort in children, adolescent, and adult patients with DMD in the U.S. who are ineligible, unable, or otherwise unwilling to enroll in a clinical study examining the efficacy of deflazacort while a new drug application is under preparation and review. Enrollment is open to all eligible patients.

intervention: Deflazacort

mechanism of action: Glucocorticoid to delay decline in muscle strength

results: https://clinicaltrials.gov/ct2/show/results/NCT02592941

last updated: November 22, 2018